Phase 2 Ovarian Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have been confirmed by tissue testing to have a specific type of cancer called high-grade serous cancer, affecting the ovaries, fallopian tubes, or the lining of the abdomen (peritoneum).
• People whose cancer has stopped responding well to platinum-based chemotherapy — specifically, those who had only one course of platinum chemotherapy and received at least 4 cycles of it, or those who had two to four courses of platinum chemotherapy and whose cancer came back or worsened during or within 6 months of the last dose.
• People who are willing to have a small tissue sample (biopsy) taken before treatment begins — a fresh sample is preferred, but a stored sample from within the last 5 years may be acceptable.
• People who have received at least 1 but no more than 4 prior rounds of systemic (whole-body) cancer treatment since their diagnosis, and for whom a single cancer drug given on its own is considered a suitable next treatment option.
• People who have previously been treated with a drug called bevacizumab, unless there was a medical reason preventing its use.
• People whose tumour tests positive for a protein called FRα must have previously been treated with a drug called mirvetuximab soravtansine, unless a medical reason prevented its use.

Who may not be able to join:

• People whose cancer is of a different tissue type, such as endometrioid, clear cell, mucinous, or sarcomatous, including mixed tumours containing any of these types, or those with low-grade or borderline ovarian cancer.
• People whose cancer never responded to their very first course of platinum chemotherapy, or whose cancer came back or worsened during or within 3 months of finishing that first course.
• People whose tumour tests positive for FRα but who have not received mirvetuximab soravtansine for any reason other than a medical contraindication.
• People who have had a significant or uncontrolled heart condition within the 6 months before the first dose of the study drug.
• People with known active cancer that has spread to the brain or spinal cord lining.
• People who have another cancer that is currently growing or requires active treatment.

Note: Other eligibility criteria set out in the study protocol may also apply (confirm with trial site).

Important: Always verify eligibility with the trial site directly before applying.